Vaxart updates: BARDA stop-work lifted, norovirus enrollment done, reverse split proposal

Vaxart, Inc.

BARDA stop-work order on COVID-19 Phase 2b trial lifted April 24, 2025; 10,000-participant portion pending BARDA approval.
Norovirus program: all 60 participants enrolled in under 2 months; topline data expected mid-2025.
Cost reductions including workforce cuts extended cash runway into 2026; seeking additional non-dilutive funding.
Annual meeting May 21, 2025; board seeks reverse stock split approval to avoid Nasdaq delisting; ISS and Glass Lewis recommend FOR.
Q1 2025 earnings call scheduled for May 13, 2025; webcast at Citizens Life Sciences Conference on May 7.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.